2X1:ETR
Abivax SA
€101.80
arrow_upward
+1.39%(+1.40) 1D
8월 21일, 오후 5시 35분 35초 GMT+2 · EUR
search
모든 종목 코드
1D
5D
1M
6M
YTD
1Y
5Y
최대
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_auto2X1의 주요 통계 생성 중...
시가
€100.80
고가
€102.60
저가
€100.40
시가총액
84.46억
평균 거래량
1.40천
거래량
3.00천
52주 최고가
€137.40
52주 최저가
€60.85
EPS
-€4.49
직원 수
80
시가
€100.80
고가
€102.60
저가
€100.40
시가총액
84.46억
평균 거래량
1.40천
거래량
3.00천
52주 최고가
€137.40
52주 최저가
€60.85
EPS
-€4.49
직원 수
80
뉴스 기사
웹 소스 및 뉴스 파트너 제공
프로필
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Abivax SA에 관한 정보